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Tom Curran, PhD, FRS, named Executive Director of
Children’s Research Institute
Tom Curran, PhD, FRS, has been named Chief Scientific Officer and
Executive Director of the Children’s Mercy Children’s Research Institute
(CRI), effective Feb. 1 [2016]
Dr. Curran comes to Children’s Mercy from the Children’s Hospital of
Philadelphia (CHOP), where he has served as Deputy Scientific Director since
2006 and Director of Basic Scientific Research in the Center for Childhood
Cancer Research since 2007. He also served as Professor of Pathology and
Laboratory Medicine at the University of Pennsylvania School of Medicine.
The Children’s Research Institute at Children’s Mercy Kansas City was
established last year to build on the hospital’s century-long history in
pediatric research and to focus the hospital’s future research efforts in four
key areas:

Tom Curran, PhD, FRS, Chief
Scientific Officer and
Executive Director of the
Children’s Research Institute.



Pediatric Genomic Medicine: Children’s Mercy has the first genome center
fully integrated inside a children’s hospital. Its Center for Pediatric Genomic
Medicine develops testing that rapidly accelerates the diagnosis and
treatment of childhood genetic diseases, including the world’s fastest wholegenome DNA sequencing test.



Clinical Pharmacology: Children’s Mercy, home to the largest pediatric
clinical pharmacology program in North America, is leading the development
and reformulation of drugs to treat children more effectively and safely.
Children are not simply “little adults” who respond to drugs according to
size. Rather, children’s developing organs and changes in metabolism
throughout infancy and childhood affect how drugs are processed by
immature or maturing bodies. Children’s Mercy is leading the way to
formulate medicines and personalize their use – known as precision medicine
– for this unique and vulnerable population.



Health Services and Outcomes: Children’s Mercy is focused on
discovering new methods for enhancing the patient-centered experience and
promoting the best possible treatment outcomes. The knowledge gained
from this research supports the hospital’s commitment to maintaining the
highest standard of care for all patients, regardless of racial, ethnic or
economic background.



Health Care Delivery: From the time of the hospital’s founding in 1897,
one of its driving missions has been to ensure all children throughout the
region have equal access to the outstanding care provided at Children’s
Mercy. Researchers in this area are focused on innovative methods for
achieving this goal through telemedicine, advanced technology, educational
programs and enhanced communications tools.
Prior to formally establishing the Children’s Research Institute last year,
Children’s Mercy brought together a panel of national experts, the External
Scientific Advisory Board. After a top-to-bottom analysis of the hospital’s
current research capabilities, the ESAB concluded, “The unique culture,

financial strength and alignment of community and hospital vision do not
exist in many other regions of the country. Collectively, these assets set the
stage for the development of a research program with extraordinary
potential.”
Following the ESAB’s report, Children’s Mercy conducted an exhaustive
national search for the right leader of its new Children’s Research Institute.
“Children’s Mercy – and all of Kansas City – are fortunate to have one of the
top scientific researchers, educators and medical leaders joining us to
accelerate Children’s Mercy’s efforts to bring translational research and
precision medicine to all children in our region,” said Michael Artman, MD,
Chairman, Department of Pediatrics.
Originally from Scotland, Dr. Curran received his PhD from London’s Imperial
Cancer Research Fund Laboratories and University College before going on
to a postdoctoral fellowship at the Salk Institute in San Diego, Calif. After
working in industry and rising to the position of Associate Director at the
Roche Institute of Molecular Biology in Nutley, N.J., he founded the
Department of Developmental Neurobiology at St. Jude Children’s Research
Hospital, Memphis Tenn., serving as Chairman from 1995 to 2006.
Dr. Curran has been elected as a Fellow of the American Association for the
Advancement of Science, the American Academy of Microbiology, the Royal
Society, London, the Academy of the American Association for Cancer
Research, and as a Member of the Institute of Medicine of the National
Academies, USA, and the American Academy of Arts and Sciences. He
served on the National Cancer Institute Board of Scientific Advisors from
2000-2005 and is a Past President of the American Association for Cancer
Research.
Dr. Curran’s research interests have spanned the areas of molecular biology,
cancer research and neurobiology. Currently, his laboratory is focused on

pediatric brain tumors, brain development and genomics, concentrating on
the goal of finding new treatments for childhood brain tumors. He has
published more than 290 research articles that have been cited more than
50,000 times.
During his tenure as Deputy Scientific Director of CHOP, Dr. Curran helped
establish a premier pediatric research program, working closely with Dr. Phil
Johnson, CSO, to manage resources and build infrastructure supporting
scientific innovation that translates discoveries into improved therapies for
children. Dr. Curran also conceived and established the Children’s Brain
Tumor Tissue Consortium, supported by the Children’s Brain Tumor
Foundation that provided a national forum for sharing of patient
biospecimens and data to accelerate progress in pediatric brain tumor
research.
“I am thrilled by the opportunity to come to Children’s Mercy Kansas City
and build the Children’s Research Institute,” said Dr. Curran. “Children’s
Mercy puts children first and our goal is to build a Research Institute,
seamlessly integrated with the Hospital that ensures our patients can take
advantage of the latest scientific advances. Science and Medicine should not
be viewed as distinct entities but rather as close partners, working in
concert, to improve the health and well-being of all children.”

